Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shivani Soni

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
The Pharmacogenomics Journal|February 5, 2021
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Eclinicalmedicine|February 23, 2023
Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trialsJingyuan Wang, Joshua Millstein, Yan Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2010
Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesisRituparna Sinha Roy, Shivani Soni, Rania Harfouche, et al.
Oncogene|July 4, 2025
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancerPriya Jayachandran, Andrew Elliott, Shivani Soni, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Targeting circadian transcriptional programs through a cis-regulatory mechanism in triple negative breast cancerYuanzhong Pan, Tsu-Pei Chiu, Lili Zhou, et al.
Clinical Colorectal Cancer|October 9, 2018
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based ChemotherapyRyuma Tokunaga, Shu Cao, Madiha Naseem, et al.
Oncogene|October 1, 2022
Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatmentFrancesca Battaglin, Priya Jayachandran, Carly Strelez, et al.
International Journal of Molecular Sciences|March 27, 2025
Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal CancerPooja Mittal, Francesca Battaglin, Yan Yang, et al.
Scientific Reports|June 10, 2021
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patientsMadiha Naseem, Shu Cao, Dongyun Yang, et al.
Journal for Immunotherapy of Cancer|November 11, 2020
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancerHiroyuki Arai, Yi Xiao, Fotios Loupakis, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
The Pharmacogenomics Journal|February 5, 2021
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Eclinicalmedicine|February 23, 2023
Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trialsJingyuan Wang, Joshua Millstein, Yan Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2010
Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesisRituparna Sinha Roy, Shivani Soni, Rania Harfouche, et al.
Oncogene|July 4, 2025
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancerPriya Jayachandran, Andrew Elliott, Shivani Soni, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Targeting circadian transcriptional programs through a cis-regulatory mechanism in triple negative breast cancerYuanzhong Pan, Tsu-Pei Chiu, Lili Zhou, et al.
Clinical Colorectal Cancer|October 9, 2018
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based ChemotherapyRyuma Tokunaga, Shu Cao, Madiha Naseem, et al.
Oncogene|October 1, 2022
Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatmentFrancesca Battaglin, Priya Jayachandran, Carly Strelez, et al.
International Journal of Molecular Sciences|March 27, 2025
Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal CancerPooja Mittal, Francesca Battaglin, Yan Yang, et al.
Scientific Reports|June 10, 2021
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patientsMadiha Naseem, Shu Cao, Dongyun Yang, et al.
Journal for Immunotherapy of Cancer|November 11, 2020
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancerHiroyuki Arai, Yi Xiao, Fotios Loupakis, et al.
Pageof 9